Literature DB >> 29285368

Role of endometriosis as a prognostic factor for post-progression survival in ovarian clear cell carcinoma.

Hiroki Ishibashi1, Masashi Takano2, Morikazu Miyamoto1, Hiroaki Soyama1, Hiroko Matsuura1, Tadashi Aoyama1, Tomoyuki Yoshikawa2, Kento Kato1, Hitoshi Tsuda3, Kenichi Furuya1.   

Abstract

The clinical significance of coexistence of endometriosis (EM) in ovarian clear cell carcinoma (CCC) has not yet been determined. The aim of the present study was to analyze the correlation of endometriosis with clinicopathological factors in CCC. The cases with CCC that received primary debulking surgery at the present hospital between 1990 and 2013 were identified. Retrospective analysis was conducted to evaluate the association between complications with EM and clinicopathological features in CCC. Of the 105 cases enrolled in the study, 45 cases were complicated with EM, and 60 cases did not have EM (non-EM). The patients with EM were diagnosed at a younger age (P=0.03), and at earlier stages (P<0.01) compared with non-EM cases. Although there was no significant difference of progression-free survival (P=0.36), complications with EM were identified as an independent prognostic factor for overall survival (OS; P<0.01) by multivariate analysis. A total of 48 patients (45.7%) developed recurrence: 18 patients in EM-group and 30 patients in non-EM group. There were no significant differences of clinicopathological factors in the treatment at recurrence between both groups. Recurrent cases in EM had significantly worse post-progression survival (PPS) compared with recurrent non-EM group (P<0.01). Multivariate analysis for PPS demonstrated that complications with EM (P<0.01) were identified as a worse prognostic factor. In CCC, the complication with EM was identified as a significant worse prognostic factor for PPS in recurrent cases. Additionally, EM was significantly associated with OS in all cases with CCC. Novel treatment strategies are therefore necessary for recurrent CCC, particularly for cases exhibiting EM.

Entities:  

Keywords:  clear cell carcinoma; endometriosis; overall survival; progression-free survival; survival post-progression

Year:  2017        PMID: 29285368      PMCID: PMC5740862          DOI: 10.3892/mco.2017.1468

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  21 in total

1.  Short response duration even in responders to chemotherapy using conventional cytotoxic agents in recurrent or refractory clear cell carcinomas of the ovary.

Authors:  Masashi Takano; Tomoko Goto; Masafumi Kato; Naoki Sasaki; Morikazu Miyamoto; Kenichi Furuya
Journal:  Int J Clin Oncol       Date:  2012-05-03       Impact factor: 3.402

2.  Prognostic value of endometriosis in patients with stage I ovarian clear cell carcinoma: Experiences at three academic institutions.

Authors:  Huimin Bai; Dongyan Cao; Fang Yuan; Guihua Sha; Jiaxin Yang; Jie Chen; Yue Wang; Zhenyu Zhang; Keng Shen
Journal:  Gynecol Oncol       Date:  2016-10-13       Impact factor: 5.482

3.  Effect of Endometriosis on the Prognosis of Ovarian Clear Cell Carcinoma: A Two-Center Cohort Study and Meta-analysis.

Authors:  Hee Seung Kim; Min A Kim; Maria Lee; Dong Hoon Suh; Kidong Kim; Jae Hong No; Hyun Hoon Chung; Yong Beom Kim; Yong Sang Song
Journal:  Ann Surg Oncol       Date:  2015-02-14       Impact factor: 5.344

4.  Cancer-Associated Mutations in Endometriosis without Cancer.

Authors:  Michael S Anglesio; Nickolas Papadopoulos; Ayse Ayhan; Tayyebeh M Nazeran; Michaël Noë; Hugo M Horlings; Amy Lum; Siân Jones; Janine Senz; Tamer Seckin; Julie Ho; Ren-Chin Wu; Vivian Lac; Hiroshi Ogawa; Basile Tessier-Cloutier; Rami Alhassan; Amy Wang; Yuxuan Wang; Joshua D Cohen; Fontayne Wong; Adnan Hasanovic; Natasha Orr; Ming Zhang; Maria Popoli; Wyatt McMahon; Laura D Wood; Austin Mattox; Catherine Allaire; James Segars; Christina Williams; Cristian Tomasetti; Niki Boyd; Kenneth W Kinzler; C Blake Gilks; Luis Diaz; Tian-Li Wang; Bert Vogelstein; Paul J Yong; David G Huntsman; Ie-Ming Shih
Journal:  N Engl J Med       Date:  2017-05-11       Impact factor: 91.245

5.  Postrecurrent oncologic outcome of patients with ovarian clear cell carcinoma.

Authors:  Hiroaki Kajiyama; Kiyosumi Shibata; Mika Mizuno; Eiko Yamamoto; Sawako Fujiwara; Tomokazu Umezu; Shiro Suzuki; Toru Nakanishi; Tetsuro Nagasaka; Fumitaka Kikkawa
Journal:  Int J Gynecol Cancer       Date:  2012-06       Impact factor: 3.437

6.  Prognosis of Japanese patients with ovarian clear cell carcinoma associated with pelvic endometriosis: clinicopathologic evaluation.

Authors:  S Komiyama; D Aoki; E Tominaga; N Susumu; Y Udagawa; S Nozawa
Journal:  Gynecol Oncol       Date:  1999-03       Impact factor: 5.482

7.  Endometriosis-associated ovarian carcinoma (EAOC): an entity distinct from other ovarian carcinomas as suggested by a nested case-control study.

Authors:  M Erzen; S Rakar; B Klancnik; K Syrjänen; B Klancar
Journal:  Gynecol Oncol       Date:  2001-10       Impact factor: 5.482

Review 8.  Epidemiology of ovarian cancer.

Authors:  Jennifer Permuth-Wey; Thomas A Sellers
Journal:  Methods Mol Biol       Date:  2009

9.  Risk and prognosis of ovarian cancer in women with endometriosis: a meta-analysis.

Authors:  H S Kim; T H Kim; H H Chung; Y S Song
Journal:  Br J Cancer       Date:  2014-02-11       Impact factor: 7.640

10.  Whole-genome sequencing revealed novel prognostic biomarkers and promising targets for therapy of ovarian clear cell carcinoma.

Authors:  Hiroaki Itamochi; Tetsuro Oishi; Nao Oumi; Satoshi Takeuchi; Kosuke Yoshihara; Mikio Mikami; Nobuo Yaegashi; Yasuhisa Terao; Kazuhiro Takehara; Kimio Ushijima; Hidemichi Watari; Daisuke Aoki; Tadashi Kimura; Toshiaki Nakamura; Yoshihito Yokoyama; Junzo Kigawa; Toru Sugiyama
Journal:  Br J Cancer       Date:  2017-07-20       Impact factor: 7.640

View more
  2 in total

1.  Clinical characteristics and prognosis of ovarian clear cell carcinoma: a 10-year retrospective study.

Authors:  Chenchen Zhu; Jing Zhu; Lili Qian; Hanyuan Liu; Zhen Shen; Dabao Wu; Weidong Zhao; Weihua Xiao; Ying Zhou
Journal:  BMC Cancer       Date:  2021-03-25       Impact factor: 4.430

2.  The histone methyltransferase SMYD2 is a novel therapeutic target for the induction of apoptosis in ovarian clear cell carcinoma cells.

Authors:  Machiko Kojima; Kenbun Sone; Katsutoshi Oda; Ryuji Hamamoto; Syuzo Kaneko; Shinya Oki; Asako Kukita; Akira Kawata; Harunori Honjoh; Yoshiko Kawata; Tomoko Kashiyama; Masakazu Sato; Ayumi Taguchi; Yuichiro Miyamoto; Michihiro Tanikawa; Tetsushi Tsuruga; Kazunori Nagasaka; Osamu Wada-Hiraike; Yutaka Osuga; Tomoyuki Fujii
Journal:  Oncol Lett       Date:  2020-08-24       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.